三唑类耐药烟曲霉的新兴威胁
侵袭性曲霉病在免疫抑制人群中致死率高,烟曲霉占侵袭性曲霉病病例的60%以上。目前对烟曲霉有稳定活性的抗真菌药仅为霉菌活性三唑类和两性霉素B,但临床和环境分离株中三唑耐药全球出现,耐药机制部分不明,耐药感染治疗经验缺乏且死亡率高。
要点
- 烟曲霉占侵袭性曲霉病病例60%以上,三唑类为一线和挽救治疗选择。
- 临床和环境分离株中三唑耐药全球出现,部分耐药机制尚不明确。
- 三唑耐药烟曲霉感染缺乏治疗经验,相关死亡率仍高。
核心结论
- 烟曲霉三唑耐药在临床和环境分离株中全球出现,构成新兴威胁,耐药感染死亡率高且治疗选择有限。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 侵袭性曲霉病每年预计导致超过200 000例危及生命的感染。
- 烟曲霉占侵袭性曲霉病病例的60%以上。
- 对烟曲霉有稳定活性的抗真菌药仅为霉菌活性三唑类和两性霉素B。
- cyp51A突变、cyp51A过表达和外排泵基因过表达均参与耐药,但部分三唑耐药仍无法解释。
临床怎么用
- 临床应关注烟曲霉三唑耐药风险,但原文未给出具体治疗推荐。
局限性
- 缺乏三唑耐药烟曲霉感染的临床治疗经验。
- 部分三唑耐药机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive aspergillosis is a leading cause of morbidity and mortality among immunocompromised populations and is predicted to cause more than 200 000 life-threatening infections each year. Aspergillus fumigatus is the most prevalent pathogen isolated from patients with invasive aspergillosis, accounting for more than 60% of all cases. Currently, the only antifungal agents available with consistent activity against A. fumigatus are the mould-active triazoles and amphotericin B, of which the triazoles commonly represent both front-line and salvage therapeutic options. Unfortunately, the treatment of infections caused by A. fumigatus has recently been further complicated by the global emergence of triazole resistance among both clinical and environmental isolates. Mutations in the A. fumigatus sterol-demethylase gene cyp51A, overexpression of cyp51A and overexpression of efflux pump genes are all known to contribute to resistance, yet much of the triazole resistance among A. fumigatus still remains unexplained. Also lacking is clinical experience with therapeutic options for the treatment of triazole-resistant A. fumigatus infections and mortality associated with these infections remains unacceptably high. Thus, further research is greatly needed to both better understand the emerging threat of triazole-resistant A. fumigatus and to develop novel therapeutic strategies to combat these resistant infections.
引用
- Rybak JM, Fortwendel JR, Rogers PD, et al. Emerging threat of triazole-resistant Aspergillus fumigatus. J Antimicrob Chemother. 2019. PMID: 30561652. doi:10.1093/jac/dky517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。